» Articles » PMID: 39768194

Intervertebral Disc Degeneration and Regeneration: New Molecular Mechanisms and Therapeutics: Obstacles and Potential Breakthrough Technologies

Overview
Journal Cells
Publisher MDPI
Date 2025 Jan 8
PMID 39768194
Authors
Affiliations
Soon will be listed here.
Abstract

Pain and disability secondary to degenerative disc disease continue to burden the healthcare system, creating an urgent need for effective, disease-modifying therapies. Contemporary research has identified potential therapies that include protein-, cellular- and/or matrix-related approaches; however, none have yet achieved a meaningful clinical impact. The tissue-specific realities of the intervertebral disc create considerable therapeutic challenges due to the disc's location, compartmentalization, hypovascularization and delicate physiological environment. Furthermore, the imaging modalities currently used in practice are largely unable to accurately identify sources of pain ostensibly discogenic in origin. These obstacles are considerable; however, recent research has begun to shed light on possible breakthrough technologies. Such breakthroughs include revolutionary imaging to better identify tissue sources of pain. Furthermore, novel molecular therapies have been shown to be able to mediate the progression of degenerative disc disease in some large animal studies, and even provide some insight into suppressing the development of tissue sources of discogenic pain. These potential breakthrough technologies have yet to be translated for clinical use.

References
1.
Nguyen C, Poiraudeau S, Rannou F . From Modic 1 vertebral-endplate subchondral bone signal changes detected by MRI to the concept of 'active discopathy'. Ann Rheum Dis. 2015; 74(8):1488-94. DOI: 10.1136/annrheumdis-2015-207317. View

2.
Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C . The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014; 73(6):968-74. DOI: 10.1136/annrheumdis-2013-204428. View

3.
de Vries S, van Doeselaar M, Meij B, Tryfonidou M, Ito K . Notochordal Cell Matrix As a Therapeutic Agent for Intervertebral Disc Regeneration. Tissue Eng Part A. 2018; 25(11-12):830-841. DOI: 10.1089/ten.TEA.2018.0026. View

4.
Matta A, Karim M, Gerami H, Jun P, Funabashi M, Kawchuk G . NTG-101: A Novel Molecular Therapy that Halts the Progression of Degenerative Disc Disease. Sci Rep. 2018; 8(1):16809. PMC: 6235869. DOI: 10.1038/s41598-018-35011-4. View

5.
Monfort J, Tardif G, Reboul P, Mineau F, Roughley P, Pelletier J . Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site. Arthritis Res Ther. 2006; 8(1):R26. PMC: 1526547. DOI: 10.1186/ar1873. View